GFL Environmental Inc. Subordinate voting shares no par value vs ResMed Inc. — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.2 (market cap $18.33B), while ResMed Inc. trades at $227.51 (market cap $31.78B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 0 Days and ResMed Inc. for 51 Days on average.
| GFL | RMD | |
|---|---|---|
Market Cap | $18.33B | $31.78B |
Volume | 2,954,733 | 1,128,382 |
Sector | Industrials | Health |
52-Week High | $46.51 | $277.88 |
52-Week Low | $33.54 | $182.82 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $25.33B | $31.14B |
Dividend Yield | 0.16% | 1.17% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →